Verona Pharma: Upcoming Conferences and Innovations in Health
Exciting Opportunities Ahead for Verona Pharma
Verona Pharma plc (NASDAQ: VRNA) recently announced a significant milestone as it prepares for its participation in a series of influential healthcare conferences taking place in March 2025. This initiative showcases the company's commitment to advancing its mission of delivering innovative solutions for chronic respiratory diseases, a sector where there is a substantial demand for effective treatments.
Upcoming Conferences in March 2025
In the upcoming month, Verona Pharma's senior management will present an overview of the company's current and future projects at two important events. The first is the TD Cowen 45th Annual Health Care Conference, scheduled for March 3, 2025. This event offers a platform for Verona Pharma to engage with investors and share insightful developments regarding their product pipeline.
TD Cowen 45th Annual Health Care Conference Details
During the TD Cowen conference, which will occur at 11:10 a.m. ET, Verona Pharma will showcase its latest advancements and position within the biopharmaceutical industry. The presentation will be accessible to investors interested in learning more about the company’s strategic direction and ongoing projects.
Leerink Partners 2025 Global Healthcare Conference
Following the TD Cowen event, Verona Pharma will also participate in the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 8:40 a.m. ET. This conference is another opportunity for the company to strengthen its relationships with stakeholders and articulate its strategies to address chronic respiratory conditions.
Webcast Availability
For those unable to attend in person, Verona Pharma ensures transparency and accessibility by providing a webcast of each conference presentation. Interested parties can easily access these webcasts through the Events and Presentations link found on the Investors section of Verona Pharma's official website.
Verona Pharma's Commitment to Innovation
Verona Pharma is at the forefront of developing therapies that fill the gap in treatment options for chronic respiratory diseases. With a primary focus on significant unmet medical needs, the company has made remarkable progress with its lead product, Ohtuvayre™ (ensifentrine). This groundbreaking inhaled therapy combines both bronchodilator and anti-inflammatory effects to provide comprehensive care for patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
Potential Applications for Ensifentrine
Ensifentrine's unique properties also make it a promising candidate for treating other serious respiratory conditions, including cystic fibrosis and asthma. The ability to address multiple diseases within the respiratory spectrum highlights Verona Pharma's innovative approach and dedication to providing effective solutions where they are needed most.
Contact Information for Inquiries
To facilitate further discussions or inquiries regarding their highlights and product developments, Verona Pharma encourages interested parties to reach out through the following contacts:
Verona Pharma plc
For general inquiries, please contact the company at Tel: +1-844-341-9901.
For Investor Relations
Victoria Stewart, Senior Director of Investor Relations and Communications, can be reached via email at IR@veronapharma.com.
For US Investor Enquiries
Investors can also connect with Argot Partners at Tel: +1-212-600-1902 or email verona@argotpartners.com.
For Media Inquiries
For international and US media inquiries, reach Ten Bridge Communications at Tel: +1-781-316-4424 or email tbcverona@tenbridgecommunications.com.
Frequently Asked Questions
What is Verona Pharma known for?
Verona Pharma is a biopharmaceutical company dedicated to developing innovative therapies for chronic respiratory diseases.
What are the upcoming conferences Verona Pharma will attend?
Verona Pharma will attend the TD Cowen Health Care Conference and the Leerink Partners 2025 Global Healthcare Conference in March 2025.
How can I watch Verona Pharma's conference presentations?
Webcasts of the conference presentations will be available on the Events and Presentations link on the Investors page of Verona Pharma's website.
What is Ohtuvayre™ (ensifentrine)?
Ohtuvayre™ (ensifentrine) is an inhaled therapy for maintaining COPD treatment, combining dual actions of bronchodilation and anti-inflammation.
How can I contact Verona Pharma for investor inquiries?
You can contact Victoria Stewart, the Senior Director of Investor Relations, at IR@veronapharma.com.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.